STOCK TITAN

Exagen Inc - XGN STOCK NEWS

Welcome to our dedicated news page for Exagen (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exagen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exagen's position in the market.

Rhea-AI Summary
Exagen Inc. to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
Rhea-AI Summary
Exagen Inc. reports Q2 2023 financial results with record CTD test delivery and increased revenue. Gross margin improves to 58.7%. Net loss decreases. Cash and cash equivalents at $31.5 million. Q3 2023 revenue guidance of $10M-$10.5M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
-
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) to Participate in Canaccord Genuity 43rd Annual Growth Conference, Presenting Autoimmune Testing Solutions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
Rhea-AI Summary
Exagen Inc., a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, on August 7, 2023. A conference call will be hosted by the President and CEO, John Aballi, and CFO, Kamal Adawi, to review the results. Interested parties can access the call via dial-in or webcast. A replay of the call will be available until August 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
Exagen Inc. announced the appointment of Paul Kim as a member of their Board of Directors. Mr. Kim is currently the CFO of Fulgent Genetics and has led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021. He brings over 30 years of accounting and finance experience to the role.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.51%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
Exagen Inc

Nasdaq:XGN

XGN Rankings

XGN Stock Data

25.51M
7.10M
30.42%
59.55%
0.12%
Dental Laboratories
Manufacturing
Link
US
Vista

About XGN

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.